RGC-32 as a potential biomarker of relapse and response to treatment with glatiramer acetate in multiple sclerosis. Kruszewski AM, Rao G, Tatomir A, Hewes D, Tegla CA, Cudrici CD, Nguyen V, Royal W, Bever CT, Rus V, et al. Exp Mol Pathol. 2015 Sep 25; 99(3):498-505. PMID: 26407760. Abstract CommentRecommendBookmarkWatch
